A Phase 2 study of T-DXd in Patients with Selected HER2 Expressing Tumors - DPT02

Study identifier:D967VC00001

ClinicalTrials.gov identifier:NCT04482309

EudraCT identifier:2020-001574-29

CTIS identifier:N/A

Recruitment Complete

Official Title

A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)

Medical condition

Part 1: Bladder, Biliary tract, Cervical, Endometrial, Ovarian, Pancreatic cancer, Rare tumors, Any tumor type excluding breast, gastric, colorectal cancer

Phase

Phase 2

Healthy volunteers

No

Study drug

Trastuzumab deruxtecan

Sex

All

Actual Enrollment

468

Study type

Interventional

Age

18 Years - 120 Years

Date

Study Start Date: 18 Aug 2020
Primary Completion Date: 08 Jun 2023
Estimated Study Completion Date: 30 Jul 2027

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Daiichi Sankyo Co., Ltd.

Inclusion and exclusion criteria